drugset
drugset / Trial / NCT05386888

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

NCT05386888 ↗

Phase 2 Completed 65 enrolled Genfleet Therapeutics (Shanghai) Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase II trial assessing the efficacy and safety of GFH018 and Toripalimab in combination with concurrent chemoradiotherapy (cCRT) in patients with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC).

Timeline

Start
2022-09-09
Primary completion
2023-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject GFH018 Small molecule 80 mg Oral
Subject Toripalimab Monoclonal antibody 3 mg/kg Intravenous
Background Carboplatin Small molecule — Intravenous
Background Cisplatin Other / unclassified — Intravenous
Background Paclitaxel Small molecule — Intravenous
Background Pemetrexed Small molecule — Intravenous

Indications

non-small cell lung carcinoma